目的 探討采用澳泰樂(lè)顆粒聯(lián)合拉米夫定治療慢性乙型肝炎的臨床療效。方法 選擇2020年6月—2021年6月在解放軍聯(lián)勤保障部隊(duì)第九八八醫(yī)院診治的88例慢性乙型肝炎患者，隨機(jī)分為對(duì)照組和治療組，每組各44例。對(duì)照組口服拉米夫定片，0.1 g/次，1次/d。治療組在對(duì)照組的基礎(chǔ)上口服澳泰樂(lè)顆粒，1袋/次，3次/d。兩組治療24周。觀察兩組患者臨床療效，比較治療前后兩組患者癥狀好轉(zhuǎn)時(shí)間，肝功能指標(biāo)丙氨酸氨基轉(zhuǎn)氨酶（ALT）、谷氨酸轉(zhuǎn)肽酶（GGT）、總膽紅素（TBIL）、天門(mén)冬氨酸氨基轉(zhuǎn)移酶（AST），血清因子γ干擾素（INF-γ）、白細(xì)胞介素-4（IL-4）、轉(zhuǎn)化生長(zhǎng)因子-β1（TGF-β1）和白細(xì)胞介素-6（IL-6）水平，及不良反應(yīng)情況。結(jié)果 治療后，治療組總有效率明顯高于對(duì)照組（97.73%vs 79.55%，P<0.05）。治療后，治療組癥狀好轉(zhuǎn)時(shí)間均明顯早于對(duì)照組（P<0.05）。治療后，兩組肝功能ALT、AST、GGT、TBIL指標(biāo)明顯下降（P<0.05），且治療組肝功能指標(biāo)水平明顯低于對(duì)照組（P<0.05）。治療后，兩組血清因子IL-6、TGF-β1水平明顯下降，而IL-4和IFN-γ水平明顯升高（P<0.05），且治療組血清因子水平均明顯好于對(duì)照組（P<0.05）。治療組不良反應(yīng)發(fā)生率為6.81%，明顯低于對(duì)照組的18.18%（P<0.05）。結(jié)論 澳泰樂(lè)顆粒聯(lián)合拉米夫定治療慢性乙型肝炎能使患者癥狀明顯好轉(zhuǎn)，改善肝功能，降低炎癥反應(yīng)。

Objective To investigate the efficacy of Aotaile Granules combined with lamivudine in treatment of hepatitis B. Methods Patients (88 cases) with hepatitis B in the 988 Hospital of the PLA Joint Logistics Support Force from June 2020 to June 2021 were randomly divided into control and treatment group, and each group had 44 cases. Patients in the control group were po administered with Lamivudine Tablets, 0.1 g/time, once daily. Patients in the treatment group were po administered with Aotaile Granules on the basis of the control group, 1 bag/time, three times daily. Patients in two groups were treated for 24 weeks. After treatment, the clinical evaluation was evaluated, the improvement time of symptom, the liver function index ALT, AST, GGT and TBIL, and the levels of serum factors IL-6, TGF-β, IL-4 and IFN-γ, and adverse reactions in two groups before and after treatment were compared. Results After treatment, the clinical effective rate of the treatment group was significantly higher than that of the control group (97.73% vs 79.55%, P < 0.05). After treatment, the improvement time of symptom in the treatment group was significantly earlier than that in the control group (P < 0.05). After treatment, the indexes of liver function ALT, AST, GGT and TBIL in two groups were significantly decreased (P < 0.05), and the liver function in the treatment group was significantly better than that in the control group (P < 0.05). After treatment, the levels of serum factors IL-6 and TGF-β1 in two groups were significantly decreased, while the levels of IL-4 and IFN-γ were significantly increased (P < 0.05), and the levels of serum factors in the treatment group were significantly better than those in the control group (P < 0.05). The incidence of adverse reactions in the treatment group was 6.81%, which was significantly lower than 18.18% in the control group (P < 0.05). Conclusion The combination of lamivudine and Aotaile Granules can significantly improve the symptoms of patients, enhance liver function, and reduce inflammatory response.

R977